Transfection

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, March 2, 2023
Acumen, Survival rate, Nanoparticle, Messenger, Pancreatic cancer, Professor, RNA, Protein, Small RNA, Research, Pharmacology, Medical school, Society, University, Cancer, Patent, Leipzig University, Neoplasm, Oncogene, Transfection, Particle size, Faculty, Paulinum (University of Leipzig), Hydrolysis, Medicine, Disease, Therapy, University of Toronto Faculty of Medicine, American Society of Clinical Oncology, ASCO, Vaccine, Pharmaceutical industry, MicroRNA

GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.

Key Points: 
  • GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.
  • SiSaf will develop miRNA Bio-Courier formulations that will be tested in pancreatic cancer models in Professor Aigner’s laboratory.
  • Under the terms of the agreement SiSaf has an exclusive option to acquire a worldwide license to a patent by the University.
  • Professor Aigner and his team have demonstrated the tumor-inhibitory potential of miR506-3p and miR24-3p in animal models of pancreatic cancer.

Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines

Retrieved on: 
Tuesday, January 31, 2023
Mirus, Transfection, Chemical engineering, Patient, Mirus Bio, Partnership, Biotechnology, CCO, Vaccine

CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ -- Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus Bio, pairing their technologies to resolve challenges related to the delivery of complex genetic materials to living human cells.

Key Points: 
  • The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines.
  • The two companies are starting a collaboration with the mission to deliver scalable genome engineering capabilities with complex payloads to traditionally difficult to manipulate cell types while improving production yields.
  • We are enthusiastic to expand our technologies in this area," said Dale Gordon, Mirus Bio CEO.
  • "Our team at Kytopen is thrilled to work with Mirus Bio and we look forward to seeing what we can accomplish together," said Greg Crescenzi, Kytopen's CCO.

BioCentriq Releases Results of Study Designed to Test Transfection of T-cells Using Kytopen's Flowfect® Technology

Retrieved on: 
Thursday, January 26, 2023
Flow cytometry, Heart, Strategic management, CRISPR, Messenger, DNA, CDMO, GFP, Cell, Partnership, Innovation, Genome-wide CRISPR-Cas9 knockout screens, Transfection, Cell engineering, Gene editing, Growth, Education minister, Vaccine

NEWARK, N.J., Jan. 26, 2023 /PRNewswire/ -- BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen's Flowfect® technology.

Key Points: 
  • NEWARK, N.J., Jan. 26, 2023 /PRNewswire/ -- BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen's Flowfect® technology.
  • The results are published in a white paper titled Efficient, Large-Scale Transfection of T-Cells Using Flowfect® Technology , which was released during last week's Advanced Therapies Week.
  • During the study, which was conducted at BioCentriq by their process development team, cells were transfected with mRNA encoding for GFP, which was analyzed using flow cytometry as a measure of transfection efficiency.
  • Transfection is an invaluable tool used in cell engineering applications to study and modify gene expression by introducing mRNA or DNA into a recipient cell.

Cell Line and Membrane Global Market Report 2022: Increases in Vaccine Production Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Science, Other Science, Biotechnology, Research, Medical Supplies, Health, Genetics, Other Health, Cell, Physiology, Immortalised cell line, Benchmarking, Porter's five forces analysis, Organic, Risk, Skin, Conditional sentence, Vaccine, Transfection, Growth, Samsung Biologics, Prevalence, Cancer, Fine chemical, Renewable energy

The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.

Key Points: 
  • The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cell line and membrane market analysis from 2021 to 2031 to identify the prevailing cell line and membrane market opportunities.
  • In-depth analysis of the cell line and membrane market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global cell line and membrane market trends, key players, market segments, application areas, and market growth strategies.

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Retrieved on: 
Monday, January 16, 2023
RNP, Data, Cell engineering, Plasmid, RNA transfection, Cas9, Cell membrane, Patient, Ministry of Education (Malaysia), Doctor of Philosophy, Potency (pharmacology), Transfection, GenScript Biotech, GMP, Vaccine, Pharmaceutical industry

Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.

Key Points: 
  • Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.
  • Launching our clinical manufacturing system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients."
  • Caption: Solupore clinical manufacturing system for non-viral delivery to enable next-generation cell therapies.
  • Provides unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery
    Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients

Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance

Retrieved on: 
Wednesday, January 18, 2023
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Liver cancer, Partnership, Hepatocellular carcinoma, Cognate, DNA, Reverse transcriptase, ATMP, CDMO, MFDS, HCC, Patient, CRL, Korean Ministry of Culture, NYSE, KFDA, US Foods, FDA, Therapy, Transfection, RNA, Corporation, Vaccine, Pharmaceutical industry, Food, IND

Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership.
  • Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.
  • RZ-001 is the first ribozyme-based RNA reprogramming approach approved by the US Food and Drug Administration (FDA) for evaluation in patients.
  • Charles River has standardized protocols for cell culture, transfection, and downstream purification, as well as a validated platform process with a proven track record.

MedTherapy, a Boston-based Biotech, plans to Reduce the Cost and Time to Manufacture CAR-T Cancer Gene therapies to One-fourth

Retrieved on: 
Monday, January 9, 2023
Dana–Farber Cancer Institute, DVM, Cancer, Harvard Medical School, Partnership, GMP, Biotechnology, Division, Disease, Patient, JPMorgan Chase, Conference, Transfection, Pharmaceutical industry, Vaccine, MD, Leukemia, Medicine

"MedTherapy was founded with a mission to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible.

Key Points: 
  • "MedTherapy was founded with a mission to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible.
  • CAR-T therapy is plagued by several constraints responsible for its exorbitant cost and complex manufacturing processes, viz.
  • Together, our integrated and innovative approaches lead to dramatic reduction in the cost and time to manufacture, and thus the reduced cost of the CAR-T cell gene therapy.
  • Our technology is being developed to manufacture CAR-T cells cancer gene therapy in a few days instead of the industry average of four to six weeks.

KromaTiD Announces Launch of Plasmid DNA Manufacturing Service

Retrieved on: 
Monday, January 9, 2023
Research, III, Transfection, DNA, Regenerative medicine, Vaccine, RUO, RNA transfection, CGMP, II

LONGMONT, Colo., Jan. 9, 2023 /PRNewswire/ -- KromaTiD, a supplier of unique next-level molecular tools and services, announced today that it has expanded its offerings to include plasmid DNA manufacturing.

Key Points: 
  • LONGMONT, Colo., Jan. 9, 2023 /PRNewswire/ -- KromaTiD, a supplier of unique next-level molecular tools and services, announced today that it has expanded its offerings to include plasmid DNA manufacturing.
  • Plasmid manufacturing is integral for the development of novel vaccines as well as cell and gene therapeutics but the high demand for this service has resulted in long wait times and considerable expense for customers.
  • KromaTiD has recently expanded its manufacturing facilitates by adding a set of state-of-the-art plasmid production suites, dedicated to supporting regenerative medicine customers from preclinical research through clinical trials and commercial production.
  • "We are excited to be launching plasmid manufacturing as a new service offering here at KromaTiD," says Chief Technology Officer Dr. Christopher Tompkins.

EQS-News: LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

Retrieved on: 
Sunday, January 22, 2023
LNP, CSO, RNA transfection, Research, CFO, API, Gesellschaft mit beschränkter Haftung, Particle size, Conference, Transfection, Nanotechnology, LEON, Fine chemical

With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.

Key Points: 
  • With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.
  • Christian Nafe, CFO of LEON, commented: “The results of our reactor studies strongly support that LEON has reached an important milestone in product development and is well on its way towards commercialization.
  • Consequently, we can measure excellent data in terms of particle size reproducibility and distribution,” added Dr. Frank Stieneker, CSO of LEON.
  • Please contact us via e-mail or LinkedIn to set up a meeting with CFO Christian Nafe and advisor Dr. Klaus Binder.

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

Retrieved on: 
Tuesday, January 3, 2023
LNP, CSO, RNA transfection, Research, CFO, API, Gesellschaft mit beschränkter Haftung, Particle size, Conference, Transfection, Nanotechnology, LEON, Fine chemical

With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.

Key Points: 
  • With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.
  • Christian Nafe, CFO of LEON, commented: “The results of our reactor studies strongly support that LEON has reached an important milestone in product development and is well on its way towards commercialization.
  • Consequently, we can measure excellent data in terms of particle size reproducibility and distribution,” added Dr. Frank Stieneker, CSO of LEON.
  • Please contact us via e-mail or LinkedIn to set up a meeting with CFO Christian Nafe and advisor Dr. Klaus Binder.